The company Neuralink, which was founded by Elon Musk and specializes in the production of brain implants, announced the start of a clinical trial in Great Britain. The aim is to test the possibility of using chips to control digital and physical devices with thought in patients with severe paralysis. About this informs Reuters.
The company is collaborating with University College London Hospital Trust and Newcastle Hospitals to carry out the research. Patients who have paralysis due to a spinal cord injury or a disease of the nervous system, including amyotrophic lateral sclerosis (ALS), will be able to participate in the project.
In 2024, Neuralink began clinical trials in humans after overcoming an objection from the US Food and Drug Administration (FDA), which had previously rejected the company’s application in 2022 due to safety concerns. Last month, Neuralink raised $650 million in its latest funding round.
According to the company, five patients with severe paralysis are already using its device to control various tools with just their thoughts. Neuralink, which was founded in 2016, has received about $1.3 billion in total investment. The current valuation of the company is approximately $9 billion.
